Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-VEGF Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT04119219
What this trial is testing

Antiangiogenic Therapy of CNV Associated With Angioid Streaks

Who this might be right for
Angioid Streaks of Macula
The Filatov Institute of Eye Diseases and Tissue Therapy 100
Large-scale testing (Phase 3)Active Not RecruitingNCT05407636
What this trial is testing

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Who this might be right for
AMDnAMDWet Age-related Macular Degeneration+3 more
AbbVie 735
Testing effectiveness (Phase 2)Looking for participantsNCT06517888
What this trial is testing

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Who this might be right for
Vestibular Schwannoma
Akouos, Inc. 27
Not applicableStudy completedNCT06881446
What this trial is testing

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions

Who this might be right for
Hepatocellular Carcinoma (HCC)
Zhongda Hospital 2,651
Large-scale testing (Phase 3)Study completedNCT03172299
What this trial is testing

Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma

Who this might be right for
Ocular Melanoma
Centre Hospitalier Universitaire de Nice 57
Post-approval studies (Phase 4)UnknownNCT02527733
What this trial is testing

Retinal Sensitivity in BRVO After Anti-VEGF Therapy

Who this might be right for
Branch Retinal Vein Occlusion
Fukushima Medical University 50
Not applicableStudy completedNCT06890026
What this trial is testing

Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Treatment-naïve
Rigshospitalet, Denmark 742
Large-scale testing (Phase 3)Study completedNCT01449682
What this trial is testing

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

Who this might be right for
Retinal Vein OcclusionMacular Edema
Retina Macula Institute 10
Large-scale testing (Phase 3)Ended earlyNCT03940690
What this trial is testing

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease

Who this might be right for
Retinal TelangiectasisCoats Disease
Fondation Ophtalmologique Adolphe de Rothschild 18
Early research (Phase 1)UnknownNCT04468997
What this trial is testing

The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)

Who this might be right for
Wet Age-related Macular Degeneration
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 67
Not applicableUnknownNCT01196325
What this trial is testing

Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy

Who this might be right for
Diabetic Macular Edema
University of Toronto 64
Not applicableEnrolling By InvitationNCT06841250
What this trial is testing

Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME

Who this might be right for
Early OCT Biomarker Changes in Response to Anti-VEGF
Sohag University 50
Not applicableStudy completedNCT03513172
What this trial is testing

Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

Who this might be right for
Post-Injection Intraocular Pressure Spikes
University of Toronto 55
Testing effectiveness (Phase 2)Study completedNCT01213082
What this trial is testing

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

Who this might be right for
Exudative Age-related Macular Degeneration
University of California, Davis 34
Not applicableActive Not RecruitingNCT04645212
What this trial is testing

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Who this might be right for
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc. 23
Not applicableStudy completedNCT04812977
What this trial is testing

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

Who this might be right for
Central Retinal Vein Occlusion With Macular Edema
Hayatabad Medical Complex 30
Not applicableEnded earlyNCT03699618
What this trial is testing

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Who this might be right for
Submacular HemorrhageWet Macular DegenerationNeovascular Age-related Macular Degeneration
Johns Hopkins University 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT02884648
What this trial is testing

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Who this might be right for
Malignant Neoplasms of Female Genital OrgansOvarian CancerFallopian Tube Cancer+1 more
M.D. Anderson Cancer Center 35
Not applicableStudy completedNCT02251366
What this trial is testing

NVAMD Satellite Study

Who this might be right for
Neovascular Age Related Macular Degeneration
Johns Hopkins University 66
Post-approval studies (Phase 4)Study completedNCT01988662
What this trial is testing

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Who this might be right for
Neovacular Age-related Macular Degeneration
Novartis Pharmaceuticals 205
Next Page